Healthcare: A Breach of Trust? Why The FDA's Taking Aim At Novartis' AveXis

<p>The FDA is investigating Novartis' subsidiary AveXis because AveXis may have manipulated data on Zolgensma, a gene therapy with a sky-high price tag and blockbuster potential. Here's what could happen next. Also, Exact Sciences goes all in on cancer diagnostics. Why the Cologuard-maker is spending $2.7 billion in a push deeper into genetic testing.</p> <p><strong>Check out more of our content here:</strong></p> <ul> <li><a href= "https://www.fool.com/podcasts/?utm_source=podcasts&utm_medium=podcasts&utm_campaign=industryfocus" target="_blank" rel="noopener">TMF's podcast portal</a></li> <li><a href="https://www.youtube.com/user/TheMotleyFool" target= "_blank" rel="noopener">YouTube</a></li> <li><a href="https://twitter.com/mfindustryfocus?lang=en" target= "_blank" rel="noopener">Twitter</a></li> <li><a href="https://m.facebook.com/groups/217114601988296">Join Our Motley Fool Podcast Facebook Group</a></li> <li><a href= "https://www.linkedin.com/company/the-motley-fool">LinkedIn</a></li> <li><a href= "https://www.fool.com/ecap/the_motley_fool/stock-up/?aid=9205&source=isusitsz0000002&ftm_cam=stockup&ftm_veh=sidebarhelp&ftm_mes=signup"> StockUp, The Motley Fool's weekly email newsletter</a></li> </ul>